Bengaluru healthtech firm Biomoneta secures USFDA nod for air purifier
Captured microbes are then neutralized on engineered microbicidal surfaces
Captured microbes are then neutralized on engineered microbicidal surfaces
DBT and BIRAC have partnered with CEPI since 2019, for cooperation on vaccine development for diseases of epidemic potential
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions
Early stage projects of up to Rs. 9 crore eligible for up to Rs. 5 crore assistance and later stage projects of up to Rs. 285 crore eligible for up to Rs. 100 crore assistance
The NDA submission follows the successful completion of a pivotal Phase III global clinical trial
This milestone marks the first-ever NDA submission to the U.S. FDA for a drug, fully discovered and developed by an Indian pharmaceutical company
The conference stressed a multi-dimensional approach required to address Antimicrobial Resistance (AMR), focusing on the right approach and strengthening awareness
Launches National IVD validation portal and protocols; highlights India’s strengthening health research ecosystem
Subscribe To Our Newsletter & Stay Updated